| Literature DB >> 36175873 |
Aida Fallahzadeh1, Yeganeh Sharifnejad Tehrani1, Ali Sheikhy1, Seyyed-Hadi Ghamari1, Esmaeil Mohammadi1, Sahar Saeedi Moghaddam1, Zahra Esfahani1,2, Maryam Nasserinejad1,3, Parnian Shobeiri1, Mohammad-Mahdi Rashidi1, Nazila Rezaei1, Mahsa Heidari-Foroozan1, Negar Rezaei4,5, Bagher Larijani6, Farshad Farzadfar1,6.
Abstract
BACKGROUND: North Africa and Middle East (NAME) has an increasing burden of chronic respiratory diseases (CRDs); however, a systematic understanding of the distribution and trends is not available. We aimed to report the trends of CRDs and attributable risk factors in this region between 1990 and 2019.Entities:
Keywords: Burden; Chronic respiratory disease; DALYs; GBD; North Africa and Middle East
Mesh:
Substances:
Year: 2022 PMID: 36175873 PMCID: PMC9521864 DOI: 10.1186/s12931-022-02187-3
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Chronic respiratory disease burden by measure in 2019, with percentage change by sex
| Measure | Sex | Incidence | Prevalence | Deaths | DALYs | YLLs | YLDs | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number (95% UI) | Rate (95% UI) | Number (95% UI) | Rate (95% UI) | Number (95% UI) | Rate (95% UI) | Number (95% UI) | Rate (95% UI) | Number (95% UI) | Rate (95% UI) | Number (95% UI) | Rate (95% UI) | ||
| Burden | Female | 2,892,958 (2,532,131 to 3,337,602) | 1082.1 (955.9 to 1234.7) | 15,508,605 (13,874,856 to 17,541,972) | 5887.6 (5331.7 to 6538.2) | 51,001 (41,322 to 59,279) | 29.1 (23.3 to 33.6) | 2,061,757 (1,756,716 to 2,352,145) | 899.7 (772.2 to 1017.4) | 1,089,221 (901,390 to 1,292,329) | 519.2 (430.9 to 610.8) | 972,536 (745,075 to 1,235,904) | 380.5 (294.1 to 474.8) |
| Male | 2,910,406 (2,493,934 to 3,409,244) | 1026.5 (895.4 to 1187.3) | 16,267,592 (14,472,613 to 18,550,695) | 5909.4 (5343.8 to 6630.6) | 77,512 (66,773 to 88,312) | 43.0 (37.0 to 48.6) | 2,697,848 (2,337,411 to 3,055,791) | 1165.2 (1023.3 to 1307.5) | 1,681,314 (1,423,688 to 1,923,462) | 779.0 (667.0 to 890.1) | 1,016,534 (778,068 to 1,291,282) | 386.1 (297.5 to 479.3) | |
| Both | 5,803,364 (5,049,564 to 6,767,369) | 1052.8 (924.3 to 1209.4) | 31,776,197 (28,349,827–36,022,813) | 5891.2 (5321.0 to 6584.3) | 128,513 (110,781 to 144,351) | 36.1 (30.9 to 40.3) | 4,759,606 (4,142,498 to 5,361,709) | 1033.4 (906.7 to 1149.3) | 2,770,536 (2,390,411 to 3,148,496) | 650.7 (563.8 to 733.1) | 1,989,070 (1,525,254 to 2,518,856) | 382.8 (298.4 to 474.7) | |
| % Change (1990–2019) | Female | 83.4 (71.5 to 96.5) | 8.8 (5.3 to 12.3) | 86.8 (78.2 to 95.3) | − 0.4 (− 3.6 to 2.8) | 56.2 (27.4 to 99.7) | − 34.3 (− 47.5 to − 15.8) | 54.5 (37.3 to 83.5) | − 27.2 (− 36.3 to − 14.5) | 24 (3.1 to 63.7) | − 41.5 (− 52.2 to − 25.2) | 113.3 (101.4 to 127.2) | 9.3 (5.4 to 13.3) |
| Male | 84.6 (72.7 to 98.7) | 12.1 (8.6 to 15.7) | 96.3 (87.6 to 105.5) | 6.6 (3.6 to 9.8) | 70.3 (41.9 to 102.1) | − 32.6 (− 44.6 to − 20.3) | 65.5 (47.5 to 87.2) | − 25.9 (− 35.4 to − 15.7) | 42.1 (19.9 to 70.3) | − 37.4 (− 47.9 to − 25.5) | 127.5 (112.0 to 145.8) | 17.8 (13.3 to 23.0) | |
| Both | 84.0 (72.4 to 97.0) | 10.3 (7.1 to 13.5) | 91.6 (83.1 to 100.0) | 2.9 (0.0 to 5.9) | 64.4 (42.5 to 88.4) | − 32.9 (− 42.0 to − 23.4) | 60.6 (47.1 to 75.9) | − 26.4 (− 33.4 to − 19.1) | 34.4 (17.1 to 54.6) | − 39.0 (− 47.1 to − 30.3) | 120.3 (106.7 to 135.8) | 13.4 (9.5 to 17.7) | |
| Attributed burden to all risk factors | Female | n/a | n/a | n/a | n/a | 25,661 (20,192 to 30,506) | 14.8 (11.3 to 17.5) | 859,987 (711,145 to 1,017,698) | 395.2 (327.4 to 465.7) | 516,635 (409,747 to 620,767) | 253.5 (201.9 to 302.8) | 343,352 (264,282 to 430,448) | 141.7 (110.0 to 174.3) |
| Male | n/a | n/a | n/a | n/a | 57,039 (47,854 to 65,008) | 32.0 (27.0 to 36.0) | 1,707,278 (1,466,720 to 1,924,884) | 780.5 (676.9 to 874.6) | 1,179,486 (984,420 to 1,359,299) | 561.1 (469.9 to 643.7) | 527,792 (413,000 to 644,058) | 219.4 (173.4 to 262.9) | |
| Both | n/a | n/a | n/a | n/a | 82,700 (70,521 to 93,662) | 23.3 (19.9 to 26.4) | 2,567,265 (2,221,981 to 2,890,442) | 590.1 (513.9 to 662.4) | 1,696,120 (1,431,688 to 1,949,413) | 409.1 (347.4 to 465.5) | 871,144 (684,153 to 1,066,190) | 181.0 (143.1 to 216.8) | |
| % Change (1990–2019) | Female | n/a | n/a | n/a | n/a | 71.5 (37.3 to 131.2) | − 30.8 (− 45.5 to − 7.3) | 82.4 (57.1 to 122.6) | − 25.4 (− 36.0 to − 7.9) | 52.6 (23.0 to 106.5) | − -36.5 (− 49.0 to − 14.3) | 158.4 (144.9 to 172.7) | 8.6 (3.1 to 14.7) |
| Male | n/a | n/a | n/a | n/a | 86.6 (52.5 to 123.3) | − 28.3 (− 41.1 to − 14.1) | 95.7 (67.6 to 125.9) | − 22.3 (− 34.0 to − 10.0) | 69.7 (36.6 to 104.4) | − 32.2 (− 45.0 to − 18.4) | 198.0 (187.1 to 210.6) | 23.7 (19.5 to 28.7) | |
| Both | n/a | n/a | n/a | n/a | 81.6 (57.3 to 109.7) | − 28.3 (− 38.4 to − 17.7) | 91.1 (71.5 to 113.6) | − 23.0 (− 31.0 to − 13.8) | 64.1 (41.7 to 91.2) | − 33.2 (− 42.4 to − 22.5) | 181.0 (170.4 to 192.5) | 17.7 (13.5 to 22.4) | |
Data in parentheses are 95% uncertainty intervals (95% UIs)
DALYs disability-adjusted life years, YLLs years of life lost, YLDs years lived with disability
Fig. 1The time trend of all ages number and age-standardized rate of CRDs. A Incidence, B prevalence, C deaths, and D DALYs
Age-standardized burden of chronic respiratory diseases in 2019, with percentage change by sex
| Measure | Sex | COPD | Pneumoconiosis | Asthma | ILD and sarcoidosis | Other CRDs | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019 (95% UI) | % Change (1990–2019) | 2019 (95% UI) | % Change (1990–2019) | 2019 (95% UI) | % Change (1990–2019) | 2019 (95% UI) | % Change (1990–2019) | 2019 (95% UI) | % Change (1990–2019) | ||
| ASIR | Female | 121.3 (113.9 to 128.9) | 26.8 (23.8 to 29.9) | 1.7 (1.3 to 2.1) | 70.3 (60.4 to 81.9) | 617.2 (506.8 to 752.3) | − 4.2 (− 9.2 to 0.2) | 342.0 (281.3 to 410.8) | 34.8 (30.2 to 39.2) | n/a | n/a |
| Male | 179.3 (171.1 to 187.9) | 39.7 (36.3 to 43.3) | 0.2 (0.2 to 0.2) | − 32.8 (− 42.2 to − 21.5) | 564.3 (442.2 to 711.7) | − 3.5 (− 8.7 to 1.4) | 282.7 (232.7 to 333.8) | 39.8 (34.8 to 45.2) | n/a | n/a | |
| ASPR | Female | 1981.2 (1876.6 to 2093.3) | 23.4 (20.8 to 26.1) | 4.1 (3.2 to 5.1) | 82.9 (69.7 to 101.1) | 4150.0 (3605.6 to 4833.4) | − 8.3 (− 12.7 to − 4.0) | 49.5 (42.4 to 57.0) | 39.5 (35.1 to 43.9) | n/a | n/a |
| Male | 2681.6 (2575.5 to 2793.8) | 36.0 (33.2 to 39.3) | 1.1 (1.0 to 1.4) | − 32.8 (− 42.2 to − 21.5) | 3508.7 (2933.2 to 4244.6) | − 7.1 (− 12.0 to − 1.6) | 39.9 (34.3 to 46.1) | 45.1 (39.9 to 50.3) | n/a | n/a | |
| ASDR | Female | 19.5 (14.7 to 22.6) | − 18.2 (− 35.4 to 28.7) | 0 (0 to 0) | 56.9 (14.7 to 119.9) | 8.2 (6.5 to 10.1) | − 57.2 (− 70.7 to − 45.3) | 1.2 (0.8 to 2.2) | 2.9 (− 20.4 to 54.1) | 0.3 (0.2 to 0.4) | 2.8 (− 39.7 to 66.8) |
| Male | 32.6 (27.5 to 37.1) | − 18.9 (− 34.3 to 0.3) | 0.1 (0.1 to 0.1) | − 27.5 (− 49.0 to 34.2) | 8.6 (6.9 to 10.9) | − 60.6 (− 68.1 to − 46.9) | 1.3 (0.9 to 2.2) | 6.0 (− 20.5 to 92.3) | 0.4 (0.2 to 0.5) | 18.0 (− 33.2 to 111.3) | |
| Age-standardized DALYs | Female | 509.1 (430.2 to 569.2) | − 12.3 (− 25.0 to 23.4) | 1.4 (1.1 to 1.8) | 70.3 (43.2 to 108.6) | 331.6 (263 to 418.6) | − 45.4 (− 57.1 to − 34.6) | 29.6 (21.2 to 51.2) | 9.1 (− 13.5 to 47.0) | 28 (23.5 to 32.8) | 42.6 (− 2.1 to 81.6) |
| Male | 786.2 (686.7 to 883) | − 12.0 (− 25.4 to 3.1) | 2.6 (2.1 to 3.1) | − 35.3 (− 54.1 to 9.6) | 317.5 (248.8 to 394.4) | − 49.5 (− 57.4 to − 37.6) | 30.5 (23.4 to 46.7) | 10.4 (− 17.9 to 74.8) | 28.4 (23.1 to 33.5) | 42.5 (− 2.3 to 89.1) | |
| Age-standardized YLLs | Female | 313.4 (239.3 to 366.1) | − 25.5 (− 39.5 to 24.3) | 0.8 (0.6 to 1.0) | 64.5 (23.5 to 132.6) | 171.5 (135.6 to 216.1) | − 60.4 (− 71.4 to − 49.8) | 24.5 (16.6 to 46.2) | 4.9 (− 18.8 to 51.2) | 9.1 (6.1 to 12.7) | − 11.7 (− 49.9 to 49.5) |
| Male | 558.3 (462.5 to 644.6) | − 22.9 (− 38.0 to − 6.0) | 2.4 (1.9 to 2.9) | − 37.5 (− 56.4 to 8.9) | 179.7 (142.1 to 230.1) | − 62.6 (− 69 to − 50.4) | 26.3 (19.4 to 42.3) | 6.9 (− 22.0 to 80.8) | 12.3 (8.1 to 16.0) | 1.9 (− 41.4 to 71.8) | |
| Age-standardized YLDs | Female | 195.7 (160.8 to 222.7) | 22.3 (19.0 to 25.7) | 0.6 (0.4 to 0.9) | 78.0 (63.2 to 96.3) | 160.1 (104.3 to 236.1) | − 8.2 (− 12.7 to − 3.5) | 5.1 (3.4 to 7.5) | 35.4 (26.0 to 45.6) | 18.9 (15.2 to 22.2) | 102.8 (92.2 to 113.4) |
| Male | 227.8 (183.1 to 266.7) | 34.8 (31.1 to 38.4) | 0.2 (0.1 to 0.3) | 21.8 (7.9 to 36.4) | 137.8 (87.7 to 205.1) | − 6.8 (− 11.9 to − 1.1) | 4.2 (2.8 to 6.2) | 39.3 (30.2 to 50.3) | 16.1 (12.6 to 19.7) | 105.2 (94.8 to 115.9) | |
Data in parentheses are 95% uncertainty intervals (95% UIs)
ASIR age-standardized incidence rate, ASPR age-standardized prevalence rate, ASDR age-standardized death rate, DALYs disability-adjusted life years, YLLs years of life lost, YLDs years lived with disability, COPD chronic obstructive pulmonary disease, ILD interstitial lung disease, CRD chronic respiratory disease
Fig. 2Age-standardized prevalence rate of CRDs in North Africa and Middle East countries in female and males in 1990 and 2019
Fig. 3The rate of CRDs. A Incidence, B prevalence, C deaths, and D DALYs categorized by age groups and sex in 1990 and 2019
Fig. 4The time trend of all ages number and age-standardized rate of CRDs. A, B Incidence, C, D prevalence, E, F deaths, G, H DALYs, I, J YLLs, and K, L YLDs categorized by 5 SDI quintiles
Fig. 5The age-standardized death rates of CRDs attributed to risk factors in North Africa and Middle East countries and region by sex in 1990 and 2019